Estamos no ar no ! Saiba mais

PolyPid

PYPD

Valor de mercado US$ 95,9 mi

4,72 USD

-0,18

3,67%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

4,90

+0,18

3,81%

1 dia

-3,67%

5 dias

-6,9%

1 mês

-9,4%

3 meses

-9,06%

6 meses

1,29%

No acumulado do ano

8,51%

1 ano

40,9%

5 anos

-97,87%

10 anos

-99,17%

Sobre: PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Funcionários: 75

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 16,7%

Neutro 83,3%

Negativo 0%

PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

Management to outline ‘PolyPid 2030', the Company's long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases Petach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd.

PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data

PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.

PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data

European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month

European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe.

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Q2 Earnings Call Highlights

PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.

PolyPid Q2 Earnings Call Highlights

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™